Linear IgA bullous dermatosis and elevated bullous interleukin-6 levels: Responsive to treatment with Anti-IL-6 receptor monoclonals.

Stanley C JordanBonnie BalzerCynthia NastJanet AtienzaKatherine LimSanjeev KumarNicholas NissenBongha Shin

Published in: Clinical case reports (2023)

Linear IgA bullous dermatosis (LABD) is a rare autoimmune/inflammatory skin condition. Here, we report on a patient who developed treatment resistant LABD. At diagnosis, elevations of IL-6 and C-reactive protein in the blood and extreme elevations of IL-6 in LABD bullous fluid were seen. The patient responded well to tocilizumab (anti-IL-6 receptor) treatment.

Keyphrases

multiple sclerosis
oxidative stress
climate change
drug delivery
cancer therapy
combination therapy
drug induced
replacement therapy